Literature DB >> 20876663

Analysis of randomized comparative clinical trial data for personalized treatment selections.

Tianxi Cai1, Lu Tian, Peggy H Wong, L J Wei.   

Abstract

Suppose that under the conventional randomized clinical trial setting, a new therapy is compared with a standard treatment. In this article, we propose a systematic, 2-stage estimation procedure for the subject-level treatment differences for future patient's disease management and treatment selections. To construct this procedure, we first utilize a parametric or semiparametric method to estimate individual-level treatment differences, and use these estimates to create an index scoring system for grouping patients. We then consistently estimate the average treatment difference for each subgroup of subjects via a nonparametric function estimation method. Furthermore, pointwise and simultaneous interval estimates are constructed to make inferences about such subgroup-specific treatment differences. The new proposal is illustrated with the data from a clinical trial for evaluating the efficacy and toxicity of a 3-drug combination versus a standard 2-drug combination for treating HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876663      PMCID: PMC3062150          DOI: 10.1093/biostatistics/kxq060

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  12 in total

1.  A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.

Authors:  M Bonetti; R D Gelber
Journal:  Stat Med       Date:  2000-10-15       Impact factor: 2.373

2.  A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.

Authors:  Patrick Royston; Willi Sauerbrei
Journal:  Stat Med       Date:  2004-08-30       Impact factor: 2.373

3.  External validity of randomised controlled trials: "to whom do the results of this trial apply?".

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

4.  The charisma of subgroups and the subgroups of CHARISMA.

Authors:  Marc A Pfeffer; John A Jarcho
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

5.  Assessing apparent treatment--covariate interactions in randomized clinical trials.

Authors:  D P Byar
Journal:  Stat Med       Date:  1985 Jul-Sep       Impact factor: 2.373

6.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

7.  Evaluating markers for selecting a patient's treatment.

Authors:  Xiao Song; Margaret Sullivan Pepe
Journal:  Biometrics       Date:  2004-12       Impact factor: 2.571

8.  AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?

Authors:  C Sabine
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

9.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

10.  Patterns of treatment effects in subsets of patients in clinical trials.

Authors:  Marco Bonetti; Richard D Gelber
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

View more
  63 in total

1.  Gene signatures revisited.

Authors:  Stuart G Baker
Journal:  J Natl Cancer Inst       Date:  2012-01-18       Impact factor: 13.506

Review 2.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

Review 3.  A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research.

Authors:  Ravi Varadhan; Jodi B Segal; Cynthia M Boyd; Albert W Wu; Carlos O Weiss
Journal:  J Clin Epidemiol       Date:  2013-05-04       Impact factor: 6.437

4.  Inequality in treatment benefits: Can we determine if a new treatment benefits the many or the few?

Authors:  Emily J Huang; Ethan X Fang; Daniel F Hanley; Michael Rosenblum
Journal:  Biostatistics       Date:  2017-04-01       Impact factor: 5.899

5.  Change-Plane Analysis for Subgroup Detection and Sample Size Calculation.

Authors:  Ailin Fan; Rui Song; Wenbin Lu
Journal:  J Am Stat Assoc       Date:  2017-04-13       Impact factor: 5.033

6.  Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.

Authors:  Brian Claggett; Lu Tian; Davide Castagno; Lee-Jen Wei
Journal:  Biostatistics       Date:  2014-08-12       Impact factor: 5.899

7.  Detecting moderator effects using subgroup analyses.

Authors:  Rui Wang; James H Ware
Journal:  Prev Sci       Date:  2013-04

8.  Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: with an Application to Treating Type 2 Diabetes Patients with Insulin Therapies.

Authors:  Yuanjia Wang; Haoda Fu; Donglin Zeng
Journal:  J Am Stat Assoc       Date:  2017-03-31       Impact factor: 5.033

9.  Evaluating marker-guided treatment selection strategies.

Authors:  Roland A Matsouaka; Junlong Li; Tianxi Cai
Journal:  Biometrics       Date:  2014-04-29       Impact factor: 2.571

10.  A single-index model with multiple-links.

Authors:  Hyung Park; Eva Petkova; Thaddeus Tarpey; R Todd Ogden
Journal:  J Stat Plan Inference       Date:  2019-07-04       Impact factor: 1.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.